Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital
E-pub ahead of print

Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Abnormal routine blood tests as predictors of mortality in acutely admitted patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Is a discard tube necessary, when drawing blood for P-Ionized calcium analysis?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Andreas Sandø
  • Martin Schultz
  • Jesper Eugen-Olsen
  • Lars Køber
  • Thomas Engstrøm
  • Henning Kelbæk
  • Erik Jørgensen
  • Kari Saunamäki
  • Lene Holmvang
  • Frants Pedersen
  • Hans Henrik Tilsted
  • Dan Høfsten
  • Steffen Helqvist
  • Peter Clemmensen
  • Kasper Iversen
Vis graf over relationer

Background: Identification of patients at high risk of non-cardiac mortality following ST-segment elevation myocardial infarction (STEMI) could guide clinicians to identify patients who require attention due to serious non-cardiac conditions after the acute phase of STEMI. The purpose of this study was to evaluate if the non-specific and prognostic biomarker of inflammation and comorbidity, soluble urokinase receptor (suPAR), could predict non-cardiac mortality in a cohort of STEMI patients. Methods: SuPAR was measured in 1,190 STEMI patients who underwent primary percutaneous coronary intervention (pPCI). The primary endpoint was non-cardiac mortality, secondary endpoints were cardiac mortality, all-cause mortality, reinfarction and periprocedural acute kidney injury. Backwards elimination of potential confounders significantly associated with the respective outcome was used to adjust associations. Results: Patients were followed for a median of 3.0 years (interquartile range 2.5– 3.6 years). Multivariate cox regression revealed that a plasma suPAR level above 3.70 ng mL −1 was associated with non-cardiac and cardiac mortality at hazard ratios 3.33 (95% confidence interval 1.67–6.63, p = 0.001, adjusted for age) and 0.99 (0.18–5.30, p = 0.98, adjusted for previous myocardial infarction and left ventricular ejection fraction), respectively. Conclusion: In patients with pPCI treated STEMI, suPAR was an independent prognostic biomarker of non-cardiac but not cardiac mortality and may identify patients with high risk of non-cardiac mortality.

TidsskriftClinical Biochemistry
StatusE-pub ahead of print - 22 mar. 2020

ID: 59614964